Astellas Expands Drug Line In Asia To Offset U.S., Europe Losses
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma is responding to the loss of patent protection on some of its key drugs by turning to Asia as a market where the company can build its drug sales. The patents are being lost in Europe and in the United States, where sales already have weakened. Astellas plans to introduce in China its Vesicare (solifenacin) for overactive bladders and its extended-relief Advagraf (tacrolimus) immunosuppressant in South Korea and Taiwan, all by the end of this year. Next year, Astellas plans to market Advagraf in China and Thailand, pending approval, Mycamine (micafungin) antifungal in India this year and in Indonesia where it already sells its Harmal (tamsulosin) for urinary disorders, sold elsewhere as Flomax. (Click here for more - a subscription may be required
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.